Ongoing treatment(s)-Biological therapy Page 2 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Is reducing the dose of imatinib effective in the treatment of chronic myeloid leukemia?

Posted by on Jan 20, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of reducing the dose of imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML). Researchers found that a lower dose of imatinib can achieve the same result as a high dose in most patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to...

Read More

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Evaluating the safety of ibrutinib in leukemia and lymphoma

Posted by on Oct 20, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

Gender affects outcomes of rituximab-based treatment

Posted by on Nov 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy.  Some background Men are more likely to develop CLL than women....

Read More

Targeted therapies: Ibrutinib appears superior to idelalisib as first treatment

Posted by on Aug 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined the order of treatment with ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (ABT-199) for chronic lymphocytic leukemia (CLL). Researchers concluded that ibrutinib appears superior to idelalisib as first treatment. Some background Early studies are reporting promising results with targeted therapies for...

Read More